|
IVAX Receives FDA Approvable Letter for Albuterol HFA in Breath-Activated Inhaler.
Publication: Business Wire Publication Date: 07-JUL-04 |
|
|
|
How to access the full article: Free access to all articles is available courtesy of your local library. To access the full article click the "See the full article" button below. You will need your US library barcode or password.
|
|
|
COPYRIGHT 2004 Business Wire
MIAMI -- IVAX Corporation (AMEX:IVX)(LSE:IVX.L) announced today that it has received an approvable letter from the United States Food and Drug Administration (FDA) for its New Drug Application (NDA) for albuterol sulfate using non-ozone-depleting, CFC-free propellant in IVAX' patented breath-activated aerosol inhaler.
Albuterol, a beta-agonist bronchodilator, is the primary rescue medicine for the relief of asthma symptoms. Over 90% of the more than 50 million albuterol inhalers sold in the U.S. last year contained chlorofluorocarbon (CFC) propellants, which are expected to be eventually removed from...
Read the full article for free courtesy of your local library.
|
|
|
|
 |
| More Articles from Business Wire |
Disney's The Haunted Mansion DVD Enchanted with InterActual Technology...
July 07, 2004
|
Don't Get Stuck This Summer Without the Soundtrack to the Disney Chann...
July 07, 2004
|
HighBeam Research Improves Tools, Adds Millions of Documents, Register...
July 07, 2004
|
Tessera and NEC Electronics Sign Technology Licensing Agreement -- Agr...
July 07, 2004
|
InVision Technologies Announces Certification of CTX 1000 Explosives D...
July 07, 2004
|
|
| Find companies classified under Pharmaceutical preparations |
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
